|
Feb 19
|
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
|
|
Feb 19
|
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative
|
|
Feb 18
|
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
|
|
Feb 18
|
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
|
|
Feb 18
|
Biogen buys rights to Stoke’s rare epilepsy drug
|
|
Feb 13
|
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
|
|
Feb 13
|
Biogen Still Offering Value, RBC Says
|
|
Feb 13
|
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
|
|
Feb 13
|
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
|
|
Feb 13
|
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
|
|
Feb 13
|
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
|
|
Feb 13
|
Biogen Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 13
|
Biogen Inc (BIIB) Q4 2024 Earnings Call Highlights: Strong EPS Growth Amid Revenue Challenges
|
|
Feb 13
|
Q4 2024 Biogen Inc Earnings Call
|
|
Feb 12
|
Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat
|
|
Feb 12
|
Biogen (BIIB) Q4 2024 Earnings Call Transcript
|
|
Feb 12
|
Vertiv, Biogen, Super Micro Computer: Market Minute
|
|
Feb 12
|
Biogen Expects Decline in 2025 Revenue, Reports Fourth-Quarter Beat
|
|
Feb 12
|
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
|
|
Feb 12
|
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
|